Development of new therapeutic artificial virus with the ability of escape from endocytosis
Project/Area Number |
23791543
|
Research Category |
Grant-in-Aid for Young Scientists (B)
|
Allocation Type | Multi-year Fund |
Research Field |
Digestive surgery
|
Research Institution | Kyushu University |
Principal Investigator |
EGAMI Takuya 九州大学, 医学研究院, 共同研究員 (40507787)
|
Project Period (FY) |
2011 – 2012
|
Project Status |
Completed (Fiscal Year 2012)
|
Budget Amount *help |
¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2012: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
Fiscal Year 2011: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
Keywords | エンドサイトーシス / アデノウイルス / 薬剤内包型人工ウイルス / 膵癌 / Drug Delibery System |
Research Abstract |
We find out the endocytosis pathway at pancreatic cancer and create an artificial virus contained anti-cancer drug. Pancreatic cancer cells highly expressed integrin β3 more than β5 are decreased expression of adenovirus-transfected gene, and pancreatic cancer cells silencing expression of integrin β 3 showed high expression of adenovirus-transfected gene. We altered an artificial virus silencing integrin β3 by protease signaling
|
Report
(3 results)
Research Products
(4 results)
-
[Journal Article] Adenoviral therapy is more effective in gemcitabine-resistant pancreatic cancer than in gemcitabine-sensitive cells2011
Author(s)
Yasui T, Ohuchida K, Zhao M, Cui L, Onimaru M, Egami T, Fujita H, Ohtsuka T, Mizumoto M, Matsumoto K, Tanaka M
-
Journal Title
Anticancer Research
Volume: 31(4)
Pages: 1279-1288
Related Report
-
-
-
[Journal Article] Adenoviral therapy is more effective in gemcitabine-resistant pancreatic cancer than in gemcitabine-sensitive cells.2011
Author(s)
Yasui T, Ohuchida K, Zhao M, Cui L, Onimaru M, Egami T, Fujita H, Ohtsuka T, Mizumoto M, Matsumoto K, Tanaka M
-
Journal Title
Anticancer Res.
Volume: 31
Pages: 1279-1288
Related Report
Peer Reviewed